Evaluation of the Effectiveness of a Physical Activity Program on the Severity of Narcolepsy

NCT ID: NCT05460052

Last Updated: 2024-01-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-26

Study Completion Date

2023-11-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder resulting from the selective loss of hypocretin neurons. Patients with NT1 suffer from excessive daytime sleepiness, disrupted nighttime sleep, and cataplexy (emotionally triggered episodes of muscle atonia). The disease is associated with numerous comorbidities such as obesity, metabolic disorders, anxiety-depressive disorders, and attentional disorders, all of which have a strong impact on quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Narcolepsy Type 1 (NT1) is a rare chronic neurological disorder resulting from the selective loss of hypocretin neurons. Patients with NT1 suffer from excessive daytime sleepiness, disrupted nighttime sleep, and cataplexy (emotionally triggered episodes of muscle atonia). The disease is associated with numerous comorbidities such as obesity, metabolic disorders, anxiety-depressive disorders, and attentional disorders, all of which have a strong impact on quality of life.

Current management is based on sleep hygiene as well as wake-promoting and anti-cataplectic medications. However, many patients complain of residual sleepiness or cataplexy. In addition, most of the proposed treatments are accompanied by side effects and have little effect on the comorbidities associated with the disease. Therapeutic alternatives are therefore needed in the management of narcolepsy.

Regular Physical Activity (RPA) is recommended by the World Health Organization (WHO) and has been shown to improve anxiety disorders, obesity, metabolic disorders, cognitive functions, sleep and quality of life.

In NT1, patients have fewer opportunities to practice RPA because of daytime sleepiness as well as increased sleep needs. Some studies suggest that cardiorespiratory performances may be lower in NT1 patients than in healthy controls, and that a higher level of physical activity may be associated with lower sleepiness and better metabolic profile in NT1 children. However, no prospective study has evaluated the feasibility of an exercise training program in NT1 or the effect of regular physical activity on disease severity.

The main objective of the study is to evaluate the effect of a physical activity training program of 3 sessions per week for 6 weeks on the severity of narcolepsy in sedentary adults with NT1.

The secondary objectives are to evaluate the feasibility of this program in an adult NT1 population, the effect of the program on comorbidities (obesity, metabolic disorders, anxiety-depressive symptoms, cognitive disorders), medication dosage and quality of life, its tolerance, and the satisfaction of the patients at short- (6 weeks) and long-term (6 months).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Narcolepsy Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immediate treatment (IT)

Patients randomized to the IT group will begin the training sessions 14 days after the inclusion.

Physical activity training program

Intervention Type OTHER

The physical activity training program will consist of 3 sessions per week for 6 weeks :

* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital
* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference.

Personalized training plan.

Intervention Type OTHER

After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.

Waiting list (WL)

Patients randomized to the WL group will receive a weekly phone call for 6 weeks.

Then, they will benefit the same training program as IT group (56 days after the inclusion).

Physical activity training program

Intervention Type OTHER

The physical activity training program will consist of 3 sessions per week for 6 weeks :

* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital
* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference.

Weekly phone call.

Intervention Type OTHER

Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.

Personalized training plan.

Intervention Type OTHER

After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Physical activity training program

The physical activity training program will consist of 3 sessions per week for 6 weeks :

* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital
* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference.

Intervention Type OTHER

Weekly phone call.

Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.

Intervention Type OTHER

Personalized training plan.

After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Narcolepsy type 1 according to International Classification of Sleep Disorders, 3rd edition (ICSD 3-2014) criteria
* Patients aged 18 to 65 years
* Patients beneficiaries of social security
* Signed consent to participate in the study
* Access to a video conferencing device (smartphone, tablet or computer)

Exclusion Criteria

* \- Patients with a high level of physical activity on the Ricci and Gagnon Questionnaire (score \>35) and/or regular physical activity in clubs
* Treatments not stabilized for less than 3 months
* Cognitive disorders incompatible with the understanding and implementation of the program
* Medical contraindication to exercise training
* Patient working night shifts
* Unstable somatic or psychiatric pathology
* Severe untreated obstructive sleep apnea syndrome (apnea/hypopnea index \>30/h)
* Pregnancy in progress or breastfeeding
* Persons deprived of liberty by a judicial or administrative decision,
* Persons admitted to a health or social institution for purposes other than research
* Persons of full age who are subject to a legal protection measure or who are unable to express their consent
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospices Civils de Lyon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laure PETER-DEREX, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hospices Civils de Lyon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de médecine du sommeil et des maladies respiratoires

Lyon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

69HCL21_1430

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pediatric Cohort Study
NCT04561427 UNKNOWN
Local Sleep in Idiopathic Hypersomnia
NCT06153615 NOT_YET_RECRUITING NA
Narcolepsy Nightmare Study
NCT05709873 COMPLETED NA
Chronic Sleep Restriction
NCT01493661 COMPLETED